Ostalo
Upper extremity deep venous thrombosis in oncological patients – case report
Marija Skoko
orcid.org/0000-0001-9411-0945
; Department for Transfusion Medicine, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Irena Mihić-Lasan
; Department for Transfusion Medicine, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Jelena Culej
; Department for Transfusion Medicine, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Tiha Vučemilo
; Department for Transfusion Medicine, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Deana Šturm
; Department for Transfusion Medicine, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Sažetak
Upper extremity deep venous thrombosis (UEDVT) makes approximately 4% to 20% of all venous thromboembolism (VTE). Cancer is the most relevant acquired thrombotic risk factor of VTE, because of its myriad of prothrombotic molecules released by neoplastic cells. In our case report we presented deep venous thrombosis (DVT) of the upper limb that is not associated with central venous catheter (CVC) or receiving chemotherapy or hormonal therapy.
A 55-year old female patient was admitted to our Department of Transfusion Medicine because of the swelling and pain in the left arm. One month earlier she underwent left segmentectomy and axillary dissection because of the breast cancer. Physical examination revealed left arm swelling and pressure pain. D-dimers were 770 μg/L (normal range 170-500 μg/L). Duplex ultrasound revealed thrombogenic mass in the left brachial vein, without total obstruction. She was treated with low molecular mass heparin (LMWH) and warfarin.
This uncommon presentation of hypercoagulable state in cancer patient points out one more time the importance of prophylactic use of anticoagulants in any hospitalized cancer patient receiving anticancer therapy. In University Hospital for Tumors we recommend anticoagulation prophylaxis for all cancer patients undergoing surgery. We use low doses of LMWH eight hours after surgery and once daily until discharge.
Ključne riječi
deep venous thrombosis; LMWH; warfarin; D-dimers
Hrčak ID:
275974
URI
Datum izdavanja:
25.11.2012.
Posjeta: 444 *